secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUPERNUS PHARMACEUTICALS, INC. (SUPN)
CIK:        0001356576
Form:       8-K
Filed at:   2025-02-18T23:59:59+00:00
Accession:  0001356576-25-000008
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Supernus SPN-820 Phase 2b misses primary endpoint in treatment-resistant depression
--------------------------------------------------------------------------------

- SPN-820 showed MADRS score change of -12.3 vs placebo -11.9 at Week 4; p=not significant.
- No statistically significant improvement on any secondary endpoints versus placebo.
- Safety profile consistent with prior trials; few adverse events and well-tolerated.
- CEO Jack Khattar expressed disappointment; will review data with partner Navitor Pharmaceuticals.
- Study enrolled ~250 adults with TRD across 40 U.S. clinical sites.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356576/000135657625000008/0001356576-25-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356576/000135657625000008/supn-20250218.htm
  HTML page:      https://secwatch.observer/filing/0001356576-25-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer